TipRanks
10x Genomics Inc (MX:TXG)
:TXG
Mexico Market
TXG
10x Genomics
RESEARCH TOOLSreports

10x Genomics (TXG) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

TXG Analyst Ratings

Moderate Buy
16Ratings
Moderate Buy
6 Buy
10 Hold
0 Sell
Based on 16 analysts giving stock ratings to
10x
Genomics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TXG Stock 12 Month Forecast

Average Price Target

$1,430.01
▲(30.00% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for 10x Genomics in the last 3 months. The average price target is $1,430.01 with a high forecast of $2,077.04 and a low forecast of $944.11. The average price target represents a 30.00% change from the last price of $1,100.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"264":"$264","1171":"$1,171","2078":"$2,078","717.5":"$717.5","1624.5":"$1,624.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2077.0392753,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.08K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1430.010070752,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.43K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":944.1087615,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$944.11</span>\n  </div></div>","useHTML":true}}],"tickPositions":[264,717.5,1171,1624.5,2078],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1623.32,1658.2214827153846,1693.1229654307692,1728.0244481461539,1762.9259308615385,1797.8274135769232,1832.7288962923078,1867.6303790076922,1902.5318617230769,1937.4333444384615,1972.3348271538462,2007.2363098692308,2042.1377925846155,{"y":2077.0392753,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1623.32,1608.4500054424616,1593.580010884923,1578.7100163273847,1563.840021769846,1548.9700272123077,1534.1000326547692,1519.2300380972308,1504.3600435396922,1489.490048982154,1474.6200544246153,1459.750059867077,1444.8800653095386,{"y":1430.010070752,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1623.32,1571.072981653846,1518.8259633076923,1466.5789449615384,1414.3319266153846,1362.0849082692307,1309.837889923077,1257.590871576923,1205.3438532307691,1153.0968348846154,1100.8498165384617,1048.6027981923078,996.3557798461538,{"y":944.1087615,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":266,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":265,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":270,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":305,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":363,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":332,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.54,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.54,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.54,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.54,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.54,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.54,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1623.32,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$2,077Average Price Target$1,430Lowest Price Target$944.11
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stephens Analyst forecast on MX:TXG
Mason Carrico
Stephens
Stephens
$1,227.34
Hold
11.58%
Upside
Downgraded
10/23/26
10x Genomics downgraded to Equal Weight from Overweight at Stephens10x Genomics downgraded to Equal Weight from Overweight at Stephens
J.P. Morgan Analyst forecast on MX:TXG
Casey Woodring
J.P. Morgan
J.P. Morgan
$944.11→$1,321.75
Hold
20.16%
Upside
Reiterated
10/16/26
J.P. Morgan Reaffirms Their Hold Rating on 10x Genomics (TXG)
TD Cowen Analyst forecast on MX:TXG
Daniel Brennan
TD Cowen
TD Cowen
$887.46→$1,321.75
Hold
20.16%
Upside
Reiterated
10/13/26
10x Genomics price target raised to $70 from $47 at TD Cowen10x Genomics price target raised to $70 from $47 at TD Cowen
Morgan Stanley Analyst forecast on MX:TXG
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
$755.29→$1,321.75
Hold
20.16%
Upside
Assigned
10/13/26
10x Genomics price target raised to $70 from $40 at Morgan Stanley10x Genomics price target raised to $70 from $40 at Morgan Stanley
Canaccord Genuity Analyst forecast on MX:TXG
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
$1,132.93→$1,888.22
Buy
71.66%
Upside
Reiterated
10/12/26
10x Genomics price target raised to $100 from $60 at Canaccord10x Genomics price target raised to $100 from $60 at Canaccord
Bank of America Securities Analyst forecast on MX:TXG
‏Avantika Dhabaria‏
Bank of America Securities
Bank of America Securities
$944.11→$1,510.57
Hold
37.32%
Upside
Reiterated
10/09/26
10x Genomics price target raised to $80 from $50 at BofA10x Genomics price target raised to $80 from $50 at BofA
Barclays Analyst forecast on MX:TXG
Luke Sergott
Barclays
Barclays
$981.87→$2,077.04
Buy
88.82%
Upside
Reiterated
10/07/26
Barclays Reaffirms Their Buy Rating on 10x Genomics (TXG)
William Blair Analyst forecast on MX:TXG
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
09/29/26
Atera’s Rapid Commercial Traction and Expanding Product Roadmap Underpin Buy Rating on 10x Genomics
Leerink Partners Analyst forecast on MX:TXG
Puneet Souda
Leerink Partners
Leerink Partners
$755.29→$1,699.4
Hold
54.49%
Upside
Reiterated
09/29/26
Leerink Partners Sticks to Its Hold Rating for 10x Genomics (TXG)
Piper Sandler Analyst forecast on MX:TXG
David Westenberg
Piper Sandler
Piper Sandler
$887.46→$1,510.57
Hold
37.32%
Upside
Assigned
09/28/26
10x Genomics price target raised to $80 from $47 at Piper Sandler10x Genomics price target raised to $80 from $47 at Piper Sandler
Argus Research Analyst forecast on MX:TXG
John Eade
Argus Research
Argus Research
$2,077.04
Buy
88.82%
Upside
Initiated
09/25/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Ascendis Pharma (NASDAQ: ASND), Lakefront Biotherapeutics (NASDAQ: LKFT) and 10x Genomics (NASDAQ: TXG)
UBS Analyst forecast on MX:TXG
Unknown Analyst
UBS
Not Ranked
UBS
$377.64→$1,283.99
Hold
16.73%
Upside
Initiated
09/08/26
UBS Sticks to Its Hold Rating for 10x Genomics (TXG)
RBC Capital Analyst forecast on MX:TXG
Dan Leonard
RBC Capital
RBC Capital
$1,321.75
Hold
20.16%
Upside
Initiated
09/01/26
10x Genomics initiated with a Sector Perform at RBC Capital10x Genomics initiated with a Sector Perform at RBC Capital
Stifel Nicolaus Analyst forecast on MX:TXG
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
$944.11
Buy
-14.17%
Downside
Reiterated
08/11/26
10x Genomics (TXG) Receives a Buy from Stifel Nicolaus
Jefferies Analyst forecast on MX:TXG
Tycho Peterson
Jefferies
Jefferies
$1,000.76
Buy
-9.02%
Downside
Reiterated
08/07/26
Analysts Are Bullish on These Healthcare Stocks: Becton Dickinson (BDX), 10x Genomics (TXG)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stephens Analyst forecast on MX:TXG
Mason Carrico
Stephens
Stephens
$1,227.34
Hold
11.58%
Upside
Downgraded
10/23/26
10x Genomics downgraded to Equal Weight from Overweight at Stephens10x Genomics downgraded to Equal Weight from Overweight at Stephens
J.P. Morgan Analyst forecast on MX:TXG
Casey Woodring
J.P. Morgan
J.P. Morgan
$944.11→$1,321.75
Hold
20.16%
Upside
Reiterated
10/16/26
J.P. Morgan Reaffirms Their Hold Rating on 10x Genomics (TXG)
TD Cowen Analyst forecast on MX:TXG
Daniel Brennan
TD Cowen
TD Cowen
$887.46→$1,321.75
Hold
20.16%
Upside
Reiterated
10/13/26
10x Genomics price target raised to $70 from $47 at TD Cowen10x Genomics price target raised to $70 from $47 at TD Cowen
Morgan Stanley Analyst forecast on MX:TXG
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
$755.29→$1,321.75
Hold
20.16%
Upside
Assigned
10/13/26
10x Genomics price target raised to $70 from $40 at Morgan Stanley10x Genomics price target raised to $70 from $40 at Morgan Stanley
Canaccord Genuity Analyst forecast on MX:TXG
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
$1,132.93→$1,888.22
Buy
71.66%
Upside
Reiterated
10/12/26
10x Genomics price target raised to $100 from $60 at Canaccord10x Genomics price target raised to $100 from $60 at Canaccord
Bank of America Securities Analyst forecast on MX:TXG
‏Avantika Dhabaria‏
Bank of America Securities
Bank of America Securities
$944.11→$1,510.57
Hold
37.32%
Upside
Reiterated
10/09/26
10x Genomics price target raised to $80 from $50 at BofA10x Genomics price target raised to $80 from $50 at BofA
Barclays Analyst forecast on MX:TXG
Luke Sergott
Barclays
Barclays
$981.87→$2,077.04
Buy
88.82%
Upside
Reiterated
10/07/26
Barclays Reaffirms Their Buy Rating on 10x Genomics (TXG)
William Blair Analyst forecast on MX:TXG
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
09/29/26
Atera’s Rapid Commercial Traction and Expanding Product Roadmap Underpin Buy Rating on 10x Genomics
Leerink Partners Analyst forecast on MX:TXG
Puneet Souda
Leerink Partners
Leerink Partners
$755.29→$1,699.4
Hold
54.49%
Upside
Reiterated
09/29/26
Leerink Partners Sticks to Its Hold Rating for 10x Genomics (TXG)
Piper Sandler Analyst forecast on MX:TXG
David Westenberg
Piper Sandler
Piper Sandler
$887.46→$1,510.57
Hold
37.32%
Upside
Assigned
09/28/26
10x Genomics price target raised to $80 from $47 at Piper Sandler10x Genomics price target raised to $80 from $47 at Piper Sandler
Argus Research Analyst forecast on MX:TXG
John Eade
Argus Research
Argus Research
$2,077.04
Buy
88.82%
Upside
Initiated
09/25/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Ascendis Pharma (NASDAQ: ASND), Lakefront Biotherapeutics (NASDAQ: LKFT) and 10x Genomics (NASDAQ: TXG)
UBS Analyst forecast on MX:TXG
Unknown Analyst
UBS
Not Ranked
UBS
$377.64→$1,283.99
Hold
16.73%
Upside
Initiated
09/08/26
UBS Sticks to Its Hold Rating for 10x Genomics (TXG)
RBC Capital Analyst forecast on MX:TXG
Dan Leonard
RBC Capital
RBC Capital
$1,321.75
Hold
20.16%
Upside
Initiated
09/01/26
10x Genomics initiated with a Sector Perform at RBC Capital10x Genomics initiated with a Sector Perform at RBC Capital
Stifel Nicolaus Analyst forecast on MX:TXG
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
$944.11
Buy
-14.17%
Downside
Reiterated
08/11/26
10x Genomics (TXG) Receives a Buy from Stifel Nicolaus
Jefferies Analyst forecast on MX:TXG
Tycho Peterson
Jefferies
Jefferies
$1,000.76
Buy
-9.02%
Downside
Reiterated
08/07/26
Analysts Are Bullish on These Healthcare Stocks: Becton Dickinson (BDX), 10x Genomics (TXG)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AMRXAmneal Pharmaceuticals
DNTHDianthus Therapeutics
REPLReplimune Group
VSTMVerastem
OVIDOvid Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering 10x Genomics

3 Months
Kyle Mikson CFACanaccord Genuity
Success Rate
17/28 ratings generated profit
61%
Average Return
+15.17%
Copying Kyle Mikson CFA's trades and holding each position for 3 Months would result in 60.71% of your transactions generating a profit, with an average return of +15.17% per trade.
1 Year
Kyle Mikson CFACanaccord Genuity
Success Rate
16/28 ratings generated profit
57%
Average Return
+107.21%
Copying Kyle Mikson CFA's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +107.21% per trade.
2 Years
Kyle Mikson CFACanaccord Genuity
Success Rate
19/28 ratings generated profit
68%
Average Return
+198.75%
Copying Kyle Mikson CFA's trades and holding each position for 2 Years would result in 67.86% of your transactions generating a profit, with an average return of +198.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TXG Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
0
Buy
10
7
12
11
12
Hold
9
14
12
16
14
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
21
24
27
26
In the current month, TXG has received 12 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. TXG average Analyst price target in the past 3 months is 1,430.01.
Each month's total comprises the sum of three months' worth of ratings.

TXG Financial Forecast

TXG Earnings Forecast

Next quarter’s earnings estimate for TXG is -$5.02 with a range of -$6.39 to -$3.31. The previous quarter’s EPS was -$2.63. TXG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TXG has Performed in-line its overall industry.
Next quarter’s earnings estimate for TXG is -$5.02 with a range of -$6.39 to -$3.31. The previous quarter’s EPS was -$2.63. TXG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TXG has Performed in-line its overall industry.

TXG Sales Forecast

Next quarter’s sales forecast for TXG is $2.78B with a range of $2.75B to $2.86B. The previous quarter’s sales results were $2.84B. TXG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TXG has Performed in-line its overall industry.
Next quarter’s sales forecast for TXG is $2.78B with a range of $2.75B to $2.86B. The previous quarter’s sales results were $2.84B. TXG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TXG has Performed in-line its overall industry.

TXG Stock Forecast FAQ

What is MX:TXG’s average 12-month price target, according to analysts?
Based on analyst ratings, 10x Genomics Inc’s 12-month average price target is 1,430.01.
    What is MX:TXG’s upside potential, based on the analysts’ average price target?
    10x Genomics Inc has 30.00% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is 10x Genomics Inc a Buy, Sell or Hold?
          10x Genomics Inc has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 10 hold ratings and 0 sell ratings.
            What is 10x Genomics Inc’s share price target?
            The average share price target for 10x Genomics Inc is 1,430.01. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $2,077.04 ,and the lowest forecast is $944.11. The average share price target represents 30.00% Increase from the current price of $1,100.
              What do analysts say about 10x Genomics Inc?
              10x Genomics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of 10x Genomics Inc?
                To buy shares of MX:TXG, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.